33
Participants
Start Date
August 15, 2017
Primary Completion Date
March 31, 2022
Study Completion Date
December 31, 2024
Irinotecan Hydrochloride
Given PO
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Sirolimus Albumin-bound Nanoparticles
Given IV
Temozolomide
Given PO
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Prisma Health Richland Hospital, Columbia
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
UCSF Medical Center-Mission Bay, San Francisco
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK